Characterization of BU09059: a novel potent selective κ-receptor antagonist

Keyphrases

• Selective Antagonist 100%
• JDTic 100%
• Receptor Antagonist 100%
• Prototypic 66%
• Derivative-based 33%
• Single Administration 33%
• U50,488 33%
• Antinociception 33%
• Nor-binaltorphimine (nor-BNI) 33%
• Receptor Binding Affinity 33%
• Potential Therapeutics 33%
• High Selectivity 33%
• Soft Drugs 33%
• Isolated Tissue 33%
• Receptor Signaling 33%
• P-hydroxyphenyl 33%
• Short-acting 33%
• Piperidine 33%
• Binding Selectivity 33%
• Psychiatric Disorders 33%
• Phenylpiperidine 33%
• Opioid Receptor Binding 33%
• Dimethyl 33%
• High Affinity 33%
• Kappa Opioid Receptor Antagonist 33%
• Pharmacodynamic Properties 33%

Neuroscience

• Receptor Antagonist 100%
• Receptor 100%
• In Vivo 40%
• Binding Affinity 20%
• Opiate 20%
• Piperidine 20%
• Receptor Binding 20%
• Kappa Antagonists 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor Antagonist 100%
• Receptor 100%
• Opiate Receptor 20%
• 3,4 Dichloro N Methyl N [2 (1 Pyrrolidinyl)cyclohexyl]benzeneacetamide 20%
• Kappa Antagonists 20%
• Piperidine Derivative 20%
• Pharmacodynamics 20%
• Antinociception 20%